TY - JOUR
T1 - Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor α inhibitor therapy
T2 - results from the Danish nationwide DANBIO registry
AU - Glintborg, Bente
AU - Østergaard, Mikkel
AU - Krogh, Niels Steen
AU - Tarp, Ulrik
AU - Manilo, Natalia
AU - Loft, Anne Gitte Rasmussen
AU - Hansen, Annette
AU - Schlemmer, Annette
AU - Fana, Victoria
AU - Lindegaard, Hanne M.
AU - Nordin, Henrik
AU - Rasmussen, Claus
AU - Ejstrup, Leif
AU - Jensen, Dorte Vendelbo
AU - Petersen, Peter Mosborg
AU - Hetland, Merete Lund
PY - 2013
Y1 - 2013
N2 - OBJECTIVE: To investigate frequencies and reasons for switching, treatment responses and drug survival in patients with ankylosing spondylitis (AS) switching tumour-necrosis-factor-α inhibitor (TNFi) treatment in routine clinical care. METHODS: AS patients were identified in the Danish nationwide DANBIO registry. Disease activity, treatment responses (50% or 20 mm reduction in Bath AS Disease Activity Index (BASDAI)), duration and rates of drug survival and predictors thereof were studied in patients receiving ≥2 different biological drugs. RESULTS: Of 1436 AS patients starting TNFi treatment, 432 patients (30%) switched to a second and 137 (10%) to a third biological drug. Compared with non-switchers, switchers were more frequently women (33%/22%), had shorter disease duration (3 years/5 years) and higher BASDAI (62(52-76) mm/56(43-69) mm (median(interquartile-range))), Bath AS Functional Index (BASFI) (54(39-71) mm/47(31-65) mm) and visual-analogue-scale (VAS) global, pain and fatigue scores when they started the first TNFi (all p
AB - OBJECTIVE: To investigate frequencies and reasons for switching, treatment responses and drug survival in patients with ankylosing spondylitis (AS) switching tumour-necrosis-factor-α inhibitor (TNFi) treatment in routine clinical care. METHODS: AS patients were identified in the Danish nationwide DANBIO registry. Disease activity, treatment responses (50% or 20 mm reduction in Bath AS Disease Activity Index (BASDAI)), duration and rates of drug survival and predictors thereof were studied in patients receiving ≥2 different biological drugs. RESULTS: Of 1436 AS patients starting TNFi treatment, 432 patients (30%) switched to a second and 137 (10%) to a third biological drug. Compared with non-switchers, switchers were more frequently women (33%/22%), had shorter disease duration (3 years/5 years) and higher BASDAI (62(52-76) mm/56(43-69) mm (median(interquartile-range))), Bath AS Functional Index (BASFI) (54(39-71) mm/47(31-65) mm) and visual-analogue-scale (VAS) global, pain and fatigue scores when they started the first TNFi (all p
U2 - 10.1136/annrheumdis-2012-201933
DO - 10.1136/annrheumdis-2012-201933
M3 - Journal article
C2 - 22941767
SN - 0003-4967
VL - 72
SP - 1149
EP - 1155
JO - Annals of the Rheumatic Diseases
JF - Annals of the Rheumatic Diseases
ER -